SAGE Therapeutics Inc (NASDAQ:SAGE) Shares Purchased by Northern Trust Corp

Share on StockTwits

Northern Trust Corp lifted its position in SAGE Therapeutics Inc (NASDAQ:SAGE) by 5.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 274,620 shares of the biopharmaceutical company’s stock after acquiring an additional 15,119 shares during the period. Northern Trust Corp owned 0.53% of SAGE Therapeutics worth $50,280,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of SAGE. Icon Wealth Partners LLC acquired a new position in shares of SAGE Therapeutics during the 1st quarter worth about $31,000. Cornerstone Advisors Inc. grew its holdings in SAGE Therapeutics by 28.3% during the 1st quarter. Cornerstone Advisors Inc. now owns 308 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 68 shares during the last quarter. Manchester Capital Management LLC acquired a new stake in SAGE Therapeutics during the 1st quarter valued at $58,000. Sawtooth Solutions LLC acquired a new stake in SAGE Therapeutics during the 1st quarter valued at $233,000. Finally, CIBC Asset Management Inc acquired a new stake in SAGE Therapeutics during the 1st quarter valued at $260,000.

Shares of SAGE stock traded up $3.26 during mid-day trading on Thursday, hitting $163.75. 4,908 shares of the company’s stock were exchanged, compared to its average volume of 357,652. SAGE Therapeutics Inc has a fifty-two week low of $79.88 and a fifty-two week high of $193.56. The stock has a 50-day simple moving average of $163.89 and a two-hundred day simple moving average of $168.25. The company has a quick ratio of 16.00, a current ratio of 16.00 and a debt-to-equity ratio of 0.03. The stock has a market cap of $8.54 billion, a price-to-earnings ratio of -20.47 and a beta of 2.55.

SAGE Therapeutics (NASDAQ:SAGE) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($3.28) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($3.32) by $0.04. The firm had revenue of $0.87 million during the quarter, compared to analyst estimates of $0.27 million. During the same quarter in the previous year, the business posted ($0.36) EPS. SAGE Therapeutics’s revenue was down 99.0% compared to the same quarter last year. As a group, analysts anticipate that SAGE Therapeutics Inc will post -13.32 earnings per share for the current fiscal year.

In related news, Director James M. Frates sold 8,000 shares of SAGE Therapeutics stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $160.58, for a total value of $1,284,640.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.60% of the stock is currently owned by company insiders.

SAGE has been the topic of a number of analyst reports. William Blair reiterated a “buy” rating on shares of SAGE Therapeutics in a report on Wednesday, July 24th. BidaskClub upgraded SAGE Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. JPMorgan Chase & Co. reiterated a “buy” rating on shares of SAGE Therapeutics in a report on Wednesday, July 24th. Oppenheimer lowered their target price on SAGE Therapeutics from $200.00 to $190.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Finally, Wedbush assumed coverage on SAGE Therapeutics in a report on Wednesday, May 22nd. They set an “outperform” rating and a $207.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $200.27.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

See Also: Overbought

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.